Imfinzi plus enfortumab vedotin cuts recurrence and death risk in bladder cancer

Perioperative Imfinzi combined with enfortumab vedotin gave a 49% lower risk of recurrence and a 42% lower risk of death for patients with muscle-invasive bladder cancer.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.